Cardiac fibroma is a benign mesenchymal neoplasm composed of fibroblasts and a collagen-rich matrix, arising predominantly within the ventricular myocardium. It is one of the main cardiac masses in children, generally second in frequency to rhabdomyoma in pediatric series, but may also be diagnosed in adults. It typically presents as a solitary mass in the ventricular wall or interventricular septum; atrial locations are less common. Histologic benignity describes the nature of the cells, whereas clinical risk depends primarily on how the mass interacts with contractile myocardium, the conduction system, valves, and coronary arteries.
A decisive feature is its ability to create an arrhythmogenic substrate even when global systolic function is preserved. Fibroma may therefore present with ventricular tachycardia or cardiac arrest before overt signs of heart failure develop. In other cases, intracavitary encroachment, deformation of the valve apparatus, or reduced ventricular compliance predominates. Cardiac growth changes the relationship between the mass and the cardiac chamber over time, but the spontaneous involution typical of cardiac rhabdomyoma is not the expected behavior of fibroma.
Current knowledge derives from pathologic series, retrospective studies, and surgical case series from specialist centers. These sources document the diversity of presentations and available treatments well, but provide less reliable estimates of the course of a small incidental lesion. In the review by Torimitsu and colleagues, which collected 178 patients reported in the literature, pediatric diagnoses and ventricular locations predominated; outcomes from a historical collection of selected cases must be distinguished from those achievable today at an expert center.
Most cardiac fibromas are diagnosed as sporadic lesions. Their occurrence during fetal life and early childhood supports an origin related to growth and differentiation processes in cardiac mesenchymal tissue. Fibroblast proliferation and matrix deposition produce a compact nodule, whose cellularity may be greater in early pediatric forms and gradually give way to more collagenized tissue. No causal association with infections, trauma, or common cardiovascular risk factors has been established.
A minority of cases are associated with Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome, an autosomal dominant tumor-predisposition condition. Involvement of PTCH1 links some of these fibromas to altered Hedgehog signaling: loss of normal control over proliferation provides a biological basis for the association. This link is clinically relevant because the cardiac finding may be detected before other manifestations of the syndrome.
Assessment looks for family history, early-onset or multiple basal cell carcinomas, odontogenic keratocysts, palmar or plantar pits, macrocephaly, and relevant skeletal abnormalities. An isolated fibroma raises suspicion, but a syndromic diagnosis requires evaluation of the clinical phenotype and molecular testing when indicated. A genetic result also determines extracardiac surveillance and counseling for relatives, so its value extends beyond merely explaining the myocardial mass.
On gross examination, fibroma is usually whitish, firm, and well demarcated from the surrounding myocardium, with a fasciculated cut surface. Visible demarcation does not guarantee a complete capsule or a uniform dissection plane. At the margins, fibrous tissue may intertwine with extensions of viable myocardium: this interdigitation contributes both to the difficulty of resection and to electrical heterogeneity at the interface. The relationship with the wall must therefore be understood as a functional interface as well as an anatomical boundary.
Microscopically, spindle-shaped fibroblastic cells are distributed among bundles of collagen, with variable amounts of elastic fibers. Cellularity and matrix density vary between lesions and between areas of the same mass. Dystrophic calcifications may be present and are particularly useful as an imaging clue when centrally located. A conventional diagnosis requires compatible morphology without the cytologic and proliferative features of a sarcomatous neoplasm. In unusual specimens, immunohistochemistry and additional testing primarily help distinguish other spindle-cell proliferations.
Fibroma must be conceptually distinguished from acquired myocardial fibrosis: a scar caused by ischemia or inflammation is a response to injury, whereas fibroma forms an organized mass that changes the architecture of the wall. Likewise, fibroelastoma denotes a different entity, predominantly endocardial and valvular. Terminological precision prevents the embolic behavior of small, mobile valvular lesions from being attributed to an intramural neoplasm.
The collagenous component has mechanical properties different from myocardium. A large mass replaces or displaces contractile tissue and may reduce ventricular compliance, impairing filling. If it protrudes into the chamber, it reduces usable cavity volume; if it involves a substantial part of the wall, it may alter regional motion and contribute to systolic dysfunction. In newborns, the ratio of tumor volume to heart size is particularly important: a nodule tolerated in an adult heart may be critically space-occupying early in life.
The effect on the valve apparatus depends on proximity to papillary muscles, chordae, and annuli. Deformation may prevent proper coaptation or obstruct inflow and outflow. The resulting regurgitation adds volume overload to the loss of functional myocardium. Epicardial arteries may run closely along the mass or be displaced by its growth; significant compression may impair perfusion, but must be demonstrated and distinguished from mere anatomical proximity.
A possible substrate for ventricular tachycardia lies in viable muscle bundles interspersed within fibrous tissue and at the interface between the mass and myocardium. Slow, heterogeneous conduction may facilitate reentry circuits; local changes in excitability may contribute to other forms of ectopic activity. A septal lesion can also involve the specialized conduction system, causing blocks or atrioventricular dissociation. Volume alone poorly describes this risk: the location of viable tissue and electrical pathways is equally important.
The risk of sudden death explains why an apparently well-tolerated fibroma requires specialist rhythm assessment. No arrhythmia on a short recording and a normal ejection fraction do not rule out a potentially unstable substrate. At the same time, data from children referred to specialist centers for severe arrhythmias cannot be applied without adjustment to every adult with an incidental finding. Risk stratification integrates clinical history, monitoring, anatomy, and treatment feasibility.
Prenatal diagnosis may occur during an anatomic ultrasound examination or after a rhythm abnormality is identified. Fetal echocardiography monitors mass growth, ventricular function, blood flows, and the onset of effusions or hydrops. A solitary ventricular mass raises the differential diagnosis of solitary rhabdomyoma; the initial diagnosis may remain probabilistic, while the hemodynamic consequences can already be assessed and guide planning for care at birth.
In infants, signs may include feeding difficulty, tachypnea, sweating, failure to thrive, pallor, or decreased responsiveness. Obstruction and arrhythmia may develop in the first weeks, whereas other children remain asymptomatic and undergo assessment because of a murmur or an incidental finding. The pattern of episodes is crucial: sustained tachycardia may quickly cause dysfunction, and sudden loss of consciousness requires consideration of an arrhythmic event even if the child subsequently appears well.
In older children and adults, clinicians look for palpitations, syncope, decreased exercise tolerance, dyspnea, and chest pain. The history clarifies the relationship with exertion, duration and mode of symptom onset, any rhythm recordings, and prior resuscitation. Older echocardiographic records may show persistence of the mass, but stability in measurements alone does not demonstrate electrical stability. Antiarrhythmic treatment, a family history of sudden death, and findings compatible with a genetic syndrome also modify the assessment.
The physical examination looks for rhythm abnormalities, murmurs from obstruction or regurgitation, and signs of poor perfusion or congestion. In infants, growth, respiratory rate, and hepatomegaly are important; in adults, concurrent heart disease should also be considered. Extracardiac examination may reveal clues to Gorlin syndrome that warrant dedicated assessment. A normal examination is compatible with an intramural mass and mainly establishes the current functional status, without replacing tumor characterization.
Transthoracic echocardiography is the initial test. Fibroma often appears as a solid, relatively homogeneous, echogenic mass embedded in the ventricular wall or septum. The examination must define its extent, margins, protrusion into the chambers, and amount of surrounding functional myocardium. Doppler assesses flow obstruction and regurgitation; ventricular assessment documents global and regional function. Searching for other masses is useful because multiplicity shifts the differential toward alternative diagnoses, though it is not an absolute rule.
Cardiac magnetic resonance imaging provides essential additional information about the matrix and the interface with myocardium. Fibrous tissue often has a signal close to that of muscle on T1-weighted images and a relatively low signal on T2-weighted images, while first-pass perfusion may be limited. After contrast, the large extracellular matrix volume favors marked late enhancement. The combination of intramural location, fibrous composition, and intense late gadolinium enhancement is particularly suggestive.
These features are biologically variable: a more cellular fibroma may show higher T2 signal, and calcifications or degenerative areas may produce hypointense or less-enhancing regions. Recognition rests on the combination of sequences, not on isolated interpretation of one parameter. Cine images also assess wall motion and dynamic relationships with the subvalvular apparatus.
Cardiac CT is useful for detecting calcifications and defining coronary relationships at high resolution, especially when these details are required for planning. The choice considers age, radiation exposure, and whether other modalities can answer the same question. In young children, MRI may require sedation; the benefits and complexity of both tests must therefore be weighed against the actual clinical question, avoiding automatic use of every available technique.
The main pediatric differential diagnosis is rhabdomyoma, often multiple, associated with tuberous sclerosis, and generally showing less intense late enhancement. A tendency to regress over time helps in stable cases, but diagnostic observation must be compatible with the clinical condition. Hemangioma has a more conspicuous vascular component, whereas lipoma shows fat characteristics. A myocardial scar follows an injury-related distribution and usually does not form the same expansile solid mass.
In atypical presentations, other spindle-cell neoplasms and infiltrative lesions are considered. Rapid progression, structural destruction, major effusion, or systemic manifestations call for critical reassessment, but none of these findings automatically establishes malignancy. Histology of resected tissue remains the definitive confirmation. A separate endomyocardial biopsy is discussed if the diagnosis remains uncertain and the result would alter management; its value must be weighed against perforation risk, nonrepresentative sampling, and the opportunity to obtain tissue during an already indicated operation.
The electrocardiogram looks for conduction disturbances, repolarization abnormalities, and ectopic beats. Prolonged monitoring can identify nonsustained tachycardias or intermittent episodes and correlate symptoms with rhythm. Patients hospitalized for major events require continuous monitoring. The duration of ambulatory monitoring is selected according to symptom frequency, age, and history; a negative short recording does not end the workup after suspicious syncope.
Electrophysiology consultation combines these findings with mass location and any documented ventricular tachycardia or fibrillation. Invasive testing may answer selected questions, but no universal inducibility-based algorithm guarantees definitive risk classification in every fibroma. Feasibility of resection changes the assessment: treatment may remove much of the substrate, whereas a residual mass or postoperative scar requires reassessment later.
Before surgery, the coronary arteries, chambers, valves, papillary muscles, and presumed course of the conduction system are mapped. Mass dimensions must be considered in relation to the wall that will remain and possible reconstruction techniques. In complex cases, joint review of imaging by cardiologists, radiologists, and surgeons helps anticipate the need for valve repair or protection of an adherent vessel. Resectability requires specific expertise: even a large lesion may be manageable with a myocardium-sparing approach.
Assessment of syndromic predisposition proceeds in parallel. When history and phenotype suggest Gorlin syndrome, genetic counseling coordinates age-appropriate testing and surveillance. Conventional fibroma does not require metastatic staging, whereas discordant findings warrant re-examination of the initial diagnosis. This distinction focuses investigations on electrical risk, cardiac function, and genuinely relevant genetic manifestations.
Surgical resection is the main treatment when fibroma causes significant arrhythmias, obstruction, dysfunction, or other major consequences. In children, arrhythmogenic potential often prompts consideration of surgery even before a prolonged symptomatic history, following specialist assessment. For asymptomatic adults with a stable mass, convincing imaging diagnosis, and substantial surgical risk, individualized surveillance may be appropriate. The decision weighs the danger posed by the lesion, the likelihood of a satisfactory functional outcome, and the consequences of surgery.
The surgical objective is to preserve a functioning heart and reduce risk by sparing myocardium, valves, and coronary circulation. Complete excision is desirable when a safe plane exists; radical removal at the cost of extensive damage may be less favorable than targeted reduction. Septal location, adherence to vessels, and subvalvular involvement may necessitate partial resections or reconstructions. The portion left in place must be described and documented for follow-up.
The series by Gikandi and colleagues, published in 2025, included 52 children who underwent resection and frequently used debulking, namely mass reduction aimed at preserving structures. Over a median follow-up of 2.4 years, no deaths or cardiac arrests were observed. This experience supports treating even large fibromas without requiring complete excision in every anatomical setting, but comes from a highly specialized center and needs long-term confirmation. The risk of scar-related arrhythmias and residual tumor growth remains relevant after initial recovery.
Antiarrhythmic drugs may control episodes during preparation for surgery or when surgery is deferred. Selection depends on arrhythmia type, function, age, and safety profile. Unstable tachycardias require urgent treatment according to hemodynamic status; emergency management takes priority over elective characterization of the mass. Good pharmacologic control does not show that the structural substrate has disappeared and must be reassessed alongside the definitive plan.
An implantable cardioverter-defibrillator is considered in selected patients, particularly after major ventricular events and when unresolved risk persists. In small children, weight, growth, access routes, and device complications are especially important. Resection may substantially alter risk and calls for joint decision-making by cardiac surgery and electrophysiology rather than automatic application of a single strategy. Ablation may have a role in selected arrhythmias, but the intramural extent of the substrate and presence of the mass can limit its efficacy.
In rare cases of severe compromise and unreconstructable anatomy, heart transplantation may be considered as a last resort. Before proceeding, the option of resection or conservative reduction must be reassessed at an experienced center. For conventional fibroma, no drug treatment has established efficacy in inducing regression; mTOR inhibitors used for some rhabdomyomas belong to a different biological context. Chemotherapy and radiotherapy are not part of usual treatment for this benign lesion.
The prognosis is often favorable after treatment that resolves mechanical effects and reduces the arrhythmogenic substrate. Preoperative function, septal location, extent, and damage from previous arrests influence recovery. The high mortality in some historical collections reflects different eras and selection criteria and does not directly describe contemporary surgical risk. Conversely, excellent results at a specialist center do not eliminate the complexity of the most extensive neonatal forms.
Follow-up includes echocardiography, rhythm assessment, and MRI when reliable measurements of residual disease, scar, and function are needed. After partial resection, the remaining portion is monitored; after complete excision, attention also includes valvular outcomes, reconstructed wall, and conduction. New palpitations or syncope warrant reassessment even if the most recent scan showed stable dimensions. Surveillance intervals are tailored to age, arrhythmic history, anatomy, and operation, because no universally validated schedule covers all presentations.
For patients managed by observation, the plan must include triggers for reconsidering this approach: reproducible growth, new arrhythmia, reduced function, emerging obstruction, or consistent symptoms. In children, measurements must be interpreted in relation to body and heart growth. A smaller mass-to-heart ratio may reduce relative crowding without indicating disappearance of fibrous tissue. Advice on physical activity primarily considers arrhythmic risk and is updated according to follow-up findings.
The main complications are ventricular tachycardia, ventricular fibrillation, cardiac arrest, conduction blocks, and heart failure. Flow obstruction, valvular regurgitation, and coronary compression may contribute to hemodynamic compromise. In fetal life, severe dysfunction may cause hydrops; after birth, circulatory adaptation makes prompt assessment of critical forms necessary. Its compact intramural nature makes embolization less typical than with myxoma and fibroelastoma.
Postoperative complications include ventricular dysfunction, valvular or coronary damage, bleeding, and conduction disturbances. Residual tumor and scarring may sustain electrical risk, which must be assessed over time rather than inferred from the final anatomical appearance alone. An implanted device also introduces its own problems, including infections and lead malfunctions. Outcome quality depends on balancing mass control with preservation of cardiac function, with surveillance continuing through transition to adult care.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.